RAMES study: is there really a role for VEGF inhibition in mesothelioma?

Porta, Camillo; Nardone, Valerio; Gray, Steven G; Correale, Pierpaolo; Mutti, Luciano

Porta, Camillo; Nardone, Valerio; Gray, Steven G; Correale, Pierpaolo; Mutti, Luciano.

Afiliación

Porta C; Department of Biomedical Sciences and Human Oncology, University of Bari A Moro, Bari, Italy.
Nardone V; Department of Precision Oncology, University Hospital of Campania L Vanvitelli, 80138 Naples, Italy. Electronic address: valerio.nardone@unicampania.it.
Gray SG; Department of Clinical Medicine, Trinity Centre for Health Sciences, Trinity Translational Medicine Institute, St James's Hospital and Trinity College, Dublin, Ireland.
Correale P; Medical Oncology Unit, Grand Metropolitan Hospital Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Mutti L; Italian Group for Research and Therapy for Mesothelioma (GIMe), Voghera, Italy.

Lancet Oncol ; 22(12): e532, 2021 12.

Article en En | MEDLINE | ID: mdl-34856142

Asunto(s)

Mesotelioma Maligno; Mesotelioma; Humanos; Mesotelioma/tratamiento farmacológico; Factor A de Crecimiento Endotelial Vascular

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Mesotelioma Maligno / Mesotelioma Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google